This study aimed to assess the psychological impact of screening for cystic fibrosis (CF) carrier status in a population of pregnant women.
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Abstract This study aimed to assess the psychological impact of screening for cystic fibrosis (CF) carrier status in a population of pregnant women. A cohort of 1798 women, who accepted the offer of testing before 18 weeks of pregnancy, filled in a self administered questionnaire seeking information on their perceived risk of carrier status and their emotional response, as well as a general health questionnaire (GHQ). Sixty-four women identified as CF carriers had partners who received a negative test result. This group and their partners were assessed, together with selected controls, on four further occasions: (1) on receiving the carrier's positive test result; (2) on receiving the partner's negative test result; (3) six weeks later; (4) six weeks after delivery. The instruments used were the GHQ and the Symptom Rating Test (SRT).
When compared to control subjects, carriers showed a significant increase in generalised psychological disturbance which could be attributed specifically to symptoms of anxiety and depression during the period (average four days) that they awaited their partner's test result. On receiving a partner's negative test result, the carriers returned to control levels and maintained this equilibrium. Although there was no significant difference in generalised psychological disturbance between partners and their selected controls, partners did become significantly more anxious and manifested feelings of inadequacy while awaiting their own test result. Both male partners and male control subjects were more likely to become anxious if their partner was distressed. (J Med Genet 1993; 30:543-8) Population carrier screening for cystic fibrosis (CF) has become possible since the identification of the cystic fibrosis gene' and the discovery that a relatively small number of mutations account for the majority of CF chromosomes in the UK population.23 One objective of carrier screening is to provide information to individual persons or couples so that they can make reproductive plans for the future. Another objective is to allow pregnant women to avoid the birth of a child with CF.
There are a number of possible approaches to CF carrier screening and The Cystic Fibrosis Trust has funded three trials to assess the feasibility of delivering screening by alternative routes.45 In Edinburgh a prenatal approach has been adopted. SRT (termed GHQ2 and SRT2). Six weeks later the couple were sent a further postal GHQ and a SRT (termed GHQ3 and SRT3) and finally six weeks after delivery the same two measures were sent (termed GHQ4 and SRT4). Control couples received a postal GHQ and a SRT at comparable intervals to carriers and partners. points (fig 3) . However, 14 of 15 (93%) partners with a positive GHQ1 had a female partner who had also scored positive. Nine of the 10 (90%) male controls who had positive GHQ1 scores had a female partner with a positive GHQ score. Males were, therefore, significantly more likely to present with psychological distress if their female counterpart was also distressed (x2, p < 0001).
SYMPTOM RATING TEST (SRT)
Five hundred and nineteen of the 576 (90%) of the total screened population with a positive threshold GHQ were interviewed and completed a threshold SRT. Among There was a significant decrease in the subscores of anxiety in SRT1 and SRT2 scores in Table 3 Median of symptom rating test (SR T) scores of carriers and controls. Table 4 Median of symptom rating test (SR T) scores of partners and controls. (table 5) . This also showed up in the subscores for depression among carriers.
Discussion
The findings from this study show that prenatal carrier screening delivered in two stages does generate some psychological disturbance. In the identified carrier there is a significant GHQ1 GHQ2 n = 63 n = 63 n= 100 n= 100 NS NS Previous studies on patients undergoing prenatal screening have indicated that once a woman perceives her pregnancy has been threatened she continues to be concerned. '6 Conversely, others have shown a dramatic return to normal once a negative test result is given.14 11 The results of this study agree with the findings of the latter. A notable effect of prenatal CF carrier screening upon two carriers was their subsequently declining a fetoprotein (AFP) screening. A further two carriers received abnormal AFP screening results and underwent amniocentesis for chromosome studies. Despite this only one of these four women was included in the 6% of carriers who stated they were against the test being offered routinely to pregnant women. A concern must be that some women may not be so resilient to multiple provoking agents during pregnancy, which could foreseeably occur if a woman experiences several positive screening test results, and particularly were she already suffering from concurrent stress. A positive aspect is that the developing area of prenatal screening will help us to consider more carefully the whole area of psychosocial support in the provision of antenatal care, which some perceive to have been neglected. '9 Psychological disturbance is considered a normal rather than a pathological response to prenatal diagnosis.20 It has been suggested that counselling efforts should support the person's attempt to cope with stress accompanying the procedure rather than not provide screening.2' The results of this study suggests that stress resulting from being identified as a CF carrier during pregnancy is short lived and that those couples faced with an intermediate risk of having a CF child cope satisfactorily.
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